7,295 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 7,295 shares of the medical equipment provider’s stock, valued at approximately $628,000.

Several other hedge funds have also recently bought and sold shares of the stock. PNC Financial Services Group Inc. increased its stake in shares of Zimmer Biomet by 9.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after purchasing an additional 13,883 shares during the last quarter. Morningstar Investment Management LLC lifted its position in shares of Zimmer Biomet by 235.4% during the 4th quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock worth $5,204,000 after buying an additional 40,610 shares during the last quarter. Robertson Stephens Wealth Management LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at about $1,131,000. CIBC Asset Management Inc boosted its stake in Zimmer Biomet by 67.6% in the fourth quarter. CIBC Asset Management Inc now owns 46,516 shares of the medical equipment provider’s stock valued at $4,183,000 after buying an additional 18,769 shares in the last quarter. Finally, First National Bank of Omaha bought a new position in Zimmer Biomet in the fourth quarter valued at about $8,919,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Trading Up 1.2%

NYSE ZBH opened at $101.41 on Thursday. The firm has a market capitalization of $19.34 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 2.72 and a beta of 0.45. The business’s 50-day moving average price is $93.40 and its two-hundred day moving average price is $91.31. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $107.85.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the company earned $2.07 earnings per share. The firm’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on ZBH. Citigroup dropped their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a report on Thursday, May 28th. JPMorgan Chase & Co. dropped their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Citizens Jmp cut their target price on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. Wells Fargo & Company decreased their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $104.42.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.